Core Viewpoint - Centene Corporation is facing an investigation regarding potential securities fraud and unlawful business practices following its withdrawal of earnings guidance due to disappointing market growth and higher-than-expected health risks [1][3]. Group 1: Company Performance - On July 1, 2025, Centene announced the withdrawal of its 2025 GAAP and adjusted diluted earnings per share (EPS) guidance, citing that market growth in 22 out of 29 states was not meeting expectations [3]. - The company indicated that the overall health risks in these states were significantly higher than anticipated, impacting its risk adjustment revenue calculations [3]. Group 2: Market Reaction - Following the announcement, Centene's stock price experienced a significant decline, falling by $22.87 per share, or 40.37%, closing at $33.78 per share on July 2, 2025 [4]. Group 3: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Centene investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving CTO Realty Growth, Inc. following a report by Wolfpack Research that accused the company of misleading investors regarding dividend sustainability and engaging in questionable financial activities [1][3]. Group 1: Investigation and Allegations - Pomerantz LLP is representing investors of CTO Realty Growth, Inc. in an investigation concerning possible securities fraud or other unlawful business practices [1]. - Wolfpack Research published a report on June 25, 2025, alleging that CTO misled investors about its dividend sustainability, leading to a significant drop in stock price [3]. - Following the release of the Wolfpack report, CTO's stock price decreased by $0.98 per share, or 5.42%, closing at $17.10 per share on the same day [3]. Group 2: Company Background - CTO Realty Growth, Inc. is listed on the NYSE under the ticker symbol CTO [1]. - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering substantial damages for victims of securities fraud [4].

Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from January 14, 2021, to June 5, 2025, seeking damages for misleading statements regarding the company's business and financial performance [1][8]. Company Overview - Petco is a specialty retailer offering a variety of pet products and services, including consumable and non-consumable products, as well as in-store veterinary and grooming services [4]. - A key business metric for Petco is comparable sales, which measures the change in period-over-period net sales from physical locations and digital sites [4]. Financial Performance and Misrepresentation - Petco claimed to benefit from pandemic-related tailwinds, including increased pet adoption rates, and positioned itself as a health-focused pet company capitalizing on trends of "pet humanization" and "premiumization" [5]. - However, as these pandemic-related tailwinds diminished, Petco's sales and profitability metrics began to decline significantly, with a notable downturn in mid-2023 [6]. - Despite worsening financial conditions, Petco's management continued to affirm optimistic financial guidance for FY 2023, including adjusted EBITDA of $520 million to $540 million and adjusted EPS of $0.40 to $0.48 [7]. Class Action Allegations - The complaint alleges that Petco's management made materially false and misleading statements about the sustainability of its business model and the strength of its product strategy, which were overstated [8]. - Specific allegations include the unsustainability of pandemic-related tailwinds, downplaying the severity of issues affecting sales, and overstating the company's ability to deliver sustainable growth [8]. Recent Financial Disclosures - On August 24, 2023, Petco revised its FY 2023 adjusted EBITDA guidance down to $460 million to $480 million and adjusted EPS to $0.24 to $0.30, leading to a 20.64% drop in stock price [9][10]. - Further negative revisions were made on November 29, 2023, with adjusted EBITDA guidance lowered to approximately $400 million and adjusted EPS to approximately $0.08, resulting in a 28.91% decline in stock price [11][12]. - In March 2024, Petco reported a GAAP net loss of $1.3 billion and acknowledged that its premium product-focused business model was not sustainable [13]. Market Reaction - Following the negative financial disclosures, Petco's stock price experienced significant declines, including a drop to $2.06 per share after the March 2024 results [14]. - On June 5, 2025, Petco reported a 1.3% year-over-year decline in comparable sales, larger than Wall Street estimates, leading to a further 23.2% drop in stock price [17][18].

Core Viewpoint - National Grid plc is under investigation for potential securities fraud and unlawful business practices following a fire incident at Heathrow Airport linked to its electrical substation [1][3]. Group 1: Investigation and Legal Actions - Pomerantz LLP is investigating claims on behalf of investors of National Grid, focusing on possible securities fraud or unlawful business practices by the company and its officers [1]. - The investigation is prompted by a report from the National Energy System Operator (NESO) indicating that National Grid was aware of a fault at an electrical substation since 2018 but failed to address it, leading to a fire that caused Heathrow Airport to shut down [3]. Group 2: Market Reaction - Following the news of the investigation and the fire incident, National Grid's American Depositary Receipt (ADR) price dropped by $3.77, or 5.07%, closing at $70.61 per ADR on July 2, 2025 [4].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, following allegations of overstating cost savings and revenue projections related to transition services agreements after its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Lawsuit Details - The lawsuit claims that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, misleading investors about the company's financial health [4]. - The case is pending in the U.S. District Court for the Southern District of New York, titled Deslande v. Fortrea Holdings Inc., et al., No. 1:25-cv-04630 [2]. Group 3: Stock Performance and Market Reaction - Following a report from Jefferies on September 25, 2024, which indicated that Fortrea's anticipated cost savings were not as significant as previously claimed, the stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full-year 2024 financial results, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed t ...

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. - Two complaints have been filed, with the first case titled Sookdeo v. Hims & Hers Health, Inc., and a subsequent similar complaint titled Yaghsizian v. Hims & Hers Health, Inc. [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy, which contains semaglutide, on its platform [3]. - Allegations state that Hims & Hers misrepresented the nature of its partnership with Novo Nordisk and claimed compliance with FDA regulations regarding the sale of compounded semaglutide [4]. Group 3: Stock Market Reaction - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 related to the company's gene therapy product, ELEVIDYS, which has been linked to severe safety risks and adverse events [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled Dolgicer v. Sarepta Therapeutics, Inc., and it involves purchasers of Sarepta securities from June 22, 2023, to June 24, 2025 [1]. - The lawsuit claims that Sarepta and its executives made false statements regarding the safety and efficacy of ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [2][3]. Group 2: Allegations and Impact - Allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to regulatory scrutiny and halt of clinical trials [3]. - On March 18, 2025, Sarepta reported a patient death due to acute liver failure linked to ELEVIDYS, causing a stock price drop of over 27% [4]. - Following further disclosures about patient deaths and regulatory actions, Sarepta's stock experienced additional declines of more than 7% and 42% on subsequent dates [5][6]. - On June 24, 2025, the FDA announced an investigation into the risks associated with ELEVIDYS, resulting in an 8% drop in stock price [7]. Group 3: Legal Process - Investors who purchased Sarepta securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [8]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [8]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [9][10]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history at $7.2 billion [10].